Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
24 drugs in development
By Therapeutic Area
top 6
R&D Momentum
100/100
Pipeline Velocity
88/100
Trial Completion Rate
72/100
Pipeline Concentration
20/100
Pipeline Freshness
72/100
Strategic Signals
Activity
Last 14 days
Tirzepatide for Treatment of CCCA
Dupilumab De-escalation in Pediatric Atopic Dermatitis: A Pilot Trial
REACT-AF: Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
Cannabidiol as an Adjunct Treatment for Alcohol Withdrawal and Craving
Feasibility of Delivering a Digital Health Intervention to Improve Food Access and Dietary Quality Among Adults With Hypertension
Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection
A Pilot Study of the Role of an Antimicrobial Herbal Formulation (Biocidin REMOVE) for the Management of Small Intestinal Bacterial Overgrowth (SIBO) in Patients With Irritable Bowel Syndrome (IBS)
PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)